{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/influenza-seasonal/prescribing-information/zanamivir/","result":{"pageContext":{"chapter":{"id":"370b7394-2bad-5d4f-ac2a-06de67bbefea","slug":"zanamivir","fullItemName":"Zanamivir","depth":2,"htmlHeader":"<!-- begin field 1354b161-6bbb-489f-8b95-3c779faca66b --><h2>Zanamivir</h2><!-- end field 1354b161-6bbb-489f-8b95-3c779faca66b -->","summary":"","htmlStringContent":"<!-- begin item 2dea3cee-972b-4c6f-a0f8-cf5cc27a03ed --><!-- end item 2dea3cee-972b-4c6f-a0f8-cf5cc27a03ed -->","topic":{"id":"7143131b-dc98-5d14-aef2-f50114a27d13","topicId":"c00149e5-18ab-49c6-8576-089384091df2","topicName":"Influenza - seasonal","slug":"influenza-seasonal","lastRevised":"Last revised in August 2020","chapters":[{"id":"415ca83c-583b-5dd7-8ce7-a67a72325836","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"39d27467-6801-59da-a28b-29a9a1aa848d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7326279e-c8e9-5783-9cb0-433a2e0c5061","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ecde5124-7df2-5d70-921e-cfa13a752476","slug":"changes","fullItemName":"Changes"},{"id":"b4d67dc6-a391-5644-a3a4-89c1c0c49e3f","slug":"update","fullItemName":"Update"}]},{"id":"3b2a94ae-a366-5ff9-8a35-6f8eb63736a1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8b66965c-fc03-5267-ac06-f0edc2bf81ea","slug":"goals","fullItemName":"Goals"},{"id":"32bc1d45-c0ea-55ed-8723-fdbf13b7196e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c5aa9558-010a-5b32-b95a-40f647ef373e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b9c5c598-f72e-505f-b951-cbe710a6af02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d0c6ad8d-5845-5dfd-b2d0-b04bb5395c62","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"48e0bfcd-fd33-552c-b052-28533a176218","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"feb6e56c-e4f6-57f4-bbee-0876089197e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bc17d7e2-a53a-595c-9f57-7080c9814001","slug":"definition","fullItemName":"Definition"},{"id":"d0475ee5-11e2-5ad5-8628-4f513e50236f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0aabed4-a912-518e-9257-8653bc7541e4","slug":"complications","fullItemName":"Complications"}]},{"id":"f81fdd28-028a-5558-92b2-90a1569692bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dcd79bc4-67e6-52b5-af13-ab18772e4c55","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4da6c7b5-c872-551a-aff9-100bef3041ca","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b540d9e5-48f5-5b1c-a8b1-8a37d951449f","fullItemName":"Management","slug":"management","subChapters":[{"id":"9cbc6ee5-b0da-5b46-9ce4-3704f7cf24a9","slug":"treating-influenza","fullItemName":"Scenario: Treating influenza"},{"id":"b82606d4-79c4-5b96-84cd-115c371c80b4","slug":"post-exposure-prophylaxis","fullItemName":"Scenario: Post-exposure prophylaxis"}]},{"id":"267c67be-5fb6-510f-b3f7-15ece61003d9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"418c695e-c703-5e30-9ec2-9bf2afeb6001","slug":"oseltamivir","fullItemName":"Oseltamivir"},{"id":"370b7394-2bad-5d4f-ac2a-06de67bbefea","slug":"zanamivir","fullItemName":"Zanamivir"}]},{"id":"83f51ef5-d6f9-5101-849d-c72bd5975126","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fe85159c-da36-5171-9b52-88d8edd9ee77","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"46f280be-d769-501b-905f-789bbf2d8454","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9904923d-c7de-53aa-8253-15c9392ece2e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3790de44-d79a-5486-b053-d09c6dccc2cc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e631b66-3030-5dd0-97e7-7504198b5a14","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ab624014-37fa-5613-976c-e2ffa65a7e90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b4d3fc-b6de-5df4-ad98-bf9ea439e342","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"267c67be-5fb6-510f-b3f7-15ece61003d9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"aca3a1da-09fb-53ff-936e-20c45bde7aa6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 64b8365d-0b84-4a19-8e4d-aa1e00b831b4 --><h3>Contraindications and cautions</h3><!-- end field 64b8365d-0b84-4a19-8e4d-aa1e00b831b4 -->","summary":"","htmlStringContent":"<!-- begin item 016b5e90-f689-46d8-8ed1-aa1e00b83179 --><!-- begin field d151d466-6a73-42cb-ba20-aa1e00b831b4 --><ul><li><strong>Do not prescribe zanamivir to people with milk protein allergy. </strong></li><li><strong>Prescribe zanamivir with caution to people with:</strong><ul><li>Asthma or chronic pulmonary disease — risk of bronchospasm. If close monitoring is not possible, avoid use.</li><li>Uncontrolled chronic illness.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field d151d466-6a73-42cb-ba20-aa1e00b831b4 --><!-- end item 016b5e90-f689-46d8-8ed1-aa1e00b83179 -->","subChapters":[]},{"id":"58124091-a3b7-5334-8dad-a5b2d3b2c209","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ff840129-a93a-46b3-9782-aa1e00b840da --><h3>Adverse effects</h3><!-- end field ff840129-a93a-46b3-9782-aa1e00b840da -->","summary":"","htmlStringContent":"<!-- begin item f514b1f5-af1a-4dfc-8a7a-aa1e00b840bb --><!-- begin field 42c35e71-5fd9-43f1-bab2-aa1e00b840da --><ul><li><strong>Common adverse effects include:</strong><ul><li>Skin reactions.</li></ul></li><li><strong>Uncommon adverse effects include:</strong><ul><li>Bronchospasm, dyspnoea, throat tightness.</li><li>Dehydration.</li><li>Oropharyngeal oedema.</li><li>Presyncope. </li><li>Severe cutaneous adverse reactions (SCARs).</li><li>Urticaria.</li></ul></li><li><strong>Other adverse effects include: </strong><ul><li>Abnormal b​​​​​​ehaviour, psychiatric disorder.</li><li>Delirium, hallucination, level of consciousness decreased. </li><li>Seizure.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 42c35e71-5fd9-43f1-bab2-aa1e00b840da --><!-- end item f514b1f5-af1a-4dfc-8a7a-aa1e00b840bb -->","subChapters":[]},{"id":"c7bfa1a6-d065-5083-8f1c-c5ffb196a8e4","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 4a4784c1-b264-4904-b231-aa1e00b85158 --><h3>Pregnancy and breastfeeding</h3><!-- end field 4a4784c1-b264-4904-b231-aa1e00b85158 -->","summary":"","htmlStringContent":"<!-- begin item 45c17260-cc2f-4216-a4bb-aa1e00b85133 --><!-- begin field 70fded87-6afc-4c89-96a1-aa1e00b85158 --><ul><li><strong>Pregnancy</strong><ul><li>Safety data is limited, however recent studies suggest there is no evidence of harm in pregnant women treated with zanamivir.</li><li>Zanamivir can be used in women who are pregnant when the potential benefit outweighs the risk (for example, during a pandemic).<ul><li>Oseltamivir is the first line option for the vast majority of pregnant women with influenza, including during seasons that are dominated by influenza A(H1N1).</li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li>Safety data is limited, however, the amount of zanamivir excreted in breastmilk is probably too small to be harmful.</li><li>Zanamivir can be used in women who are breastfeeding when the potential benefit outweighs the risk (for example, during a pandemic).</li><li>However, the manufacturer advises that as a risk to the breastfed child cannot be excluded a decision must be made whether to discontinue breastfeeding or to discontinue/abstain from treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>]</p><!-- end field 70fded87-6afc-4c89-96a1-aa1e00b85158 --><!-- end item 45c17260-cc2f-4216-a4bb-aa1e00b85133 -->","subChapters":[]},{"id":"910afe85-c453-5db6-a233-4d940a7bb263","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9f8fde30-fca0-4fcc-b4e2-aa1e00b85ce8 --><h3>Drug interactions</h3><!-- end field 9f8fde30-fca0-4fcc-b4e2-aa1e00b85ce8 -->","summary":"","htmlStringContent":"<!-- begin item f0bc20c4-e662-4991-84f8-aa1e00b85cac --><!-- begin field 3728fdab-06dc-41a1-8eb1-aa1e00b85ce8 --><ul><li>There are no significant drug interactions for zanamivir.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Preston, 2016</a>] </p><!-- end field 3728fdab-06dc-41a1-8eb1-aa1e00b85ce8 --><!-- end item f0bc20c4-e662-4991-84f8-aa1e00b85cac -->","subChapters":[]},{"id":"7a75bcf8-8bc3-544f-b76f-cc527cb22a7e","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 44d9bd92-8051-412a-99aa-aa2a00d4b84f --><h3>Dose</h3><!-- end field 44d9bd92-8051-412a-99aa-aa2a00d4b84f -->","summary":"","htmlStringContent":"<!-- begin item 31a6eab8-d1df-4164-a717-aa2a00d4b7f8 --><!-- begin field a94bc9b5-17c1-40d2-afb0-aa2a00d4b84f --><ul><li>The dose of inhaled zanamivir for adults and children aged over 5 years for: <ul><li><strong>Treatment of influenza</strong> is 10 mg twice daily for 5 days.</li><li><strong>Post exposure prophylaxis of influenza</strong> is 10 mg once daily for 10 days (up to 28 days during an epidemic).</li><li>Treatment of suspected or confirmed oseltamivir resistant influenza is 10 mg twice a day for up to 10 days (off-label duration).</li></ul></li><li>Zanamivir is not licensed for use in children aged under 5 years.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>]</p><!-- end field a94bc9b5-17c1-40d2-afb0-aa2a00d4b84f --><!-- end item 31a6eab8-d1df-4164-a717-aa2a00d4b7f8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}